
Fig. 1.



3283, cyclo VEGF$_{189}$ (152-163) mutant: CVQDPQTOKOSC
3284, cyclo VEGF$_{189}$ (154-161) mutant: CDPQTOKC
3285, cyclo VEGF$_{189}$ (152-163) mutant: YCVQDPQTOKOSCY
3286, dicyclo VEGF$_{165}$ (111-138): ARQENPCGPC'SERRKHLFVQDPQTCKC'S
3287/F9, dicyclo VEGF$_{165}$ (138-165): SC'KNTDSRCKARQLELNERTC'RCDKPRR
3287/F10, dicyclo VEGF$_{165}$ (138-165): SC'KNTDSRCKARQLELNERTC'RCDKPRR

O = Aminobutyric acid

Fig. 2.



o HUVEC, IC50 = 26 μM
• PAE/NP1,IC50 = 3 μM
PAE/NP1
PAE/Flt1
PAE/KDR
Specific 125I-VEGF binding, % of control
log [EG3287] (M)
150
100
50
0
-7
-6
-5
-4
-3

Fig. 3.




EG3287, μM
0 10 30 100
VEGF-A + EG3287
0 10 30 100
pY1054/1059-KDR
Total KDR

Fig. 4.


● VEGF165, IC50 = 1 nM
○ EG3287, IC50 = 3 μM
Specific 125I-VEGF binding, % of control
150
100
50
0
-50
-13
-12
-11
-10
-9
-8
-7
-6
-5
-4
-3
-2
Concentration, log M